Pfizer Inc. Stock
Pfizer Inc. Stock
Pros and Cons of Pfizer Inc. in the next few years
Pros
Cons
Performance of Pfizer Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | -0.110% | -0.022% | -7.960% | 7.183% | 6.227% | -35.322% | -32.127% |
| BioMarin Pharmaceutical Inc. | 0.590% | -0.022% | -5.424% | -17.043% | -10.589% | -48.107% | -29.638% |
| Biogen Inc. | -0.150% | 3.296% | 5.150% | 50.228% | 7.921% | -44.003% | -28.474% |
| Zoetis Inc. A | -0.150% | -3.432% | -5.888% | -31.193% | -10.376% | -43.065% | -33.550% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.When diving into the financials of Pfizer Inc. (PFE), a major player within the pharmaceuticals industry, a mixed picture starts to emerge. On the one hand, the company boasts a solid revenue stream and demonstrates a commendable operating margin, creating an impression of profitability. On the other hand, several warning signs appear in the form of declining growth metrics and concerns over income stability. Now, let’s break down the analysis into pros and cons to provide a comprehensive view.
Strong Revenue Performance: Pfizer reported a total revenue of approximately $54.89 billion over the trailing twelve months. This figure suggests that the company has maintained a robust sales figure, driven largely by their pharmaceutical portfolio, including well-known products and newly developed vaccines.
Healthy Operating Margins: The operating margin, standing at around 31.63%, illustrates the company's efficiency in turning sales into profit. This is relatively strong for the pharmaceutical sector, indicating that Pfizer is effectively managing its operating expenses relative to its revenue.
Comments
News
Eli Lilly Just Announced Fantastic News for Shareholders
Eli Lilly's (NYSE: LLY) broad range of drugs has helped build its success over time, but in recent years, one particular portfolio has supercharged growth. I'm talking about the company's weight
Pfizer Stock: Still Priced Like It's Dead Money
During the coronavirus pandemic, investors got a little too excited about Pfizer's (NYSE: PFE) vaccine opportunity. When demand for COVID vaccines cooled off, the stock plunged. And it hasn't really
Pfizer Just Scored a Win That Wall Street Can't Ignore
Pfizer (NYSE: PFE) recently reached settlements with three generic drugmakers -- Hikma, Cipla, and Dexcel -- to extend the patent protection of Vyndamax, one of its best-selling drugs, through June